Research progress on ferroptosis and PARP inhibitors in ovarian cancer: action mechanisms and resistance mechanisms DOI Creative Commons
Jiqing Zhang, Dan Ouyang, Mu Liu

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: April 24, 2025

Ovarian cancer, a gynecologic malignancy with high mortality rates, faces persistent therapeutic challenges due to acquired resistance and frequent recurrence conventional therapies. While poly (ADP-ribose) polymerase (PARP) inhibitors have primarily transformed clinical outcomes through the synthetic lethality mechanism, their long-term efficacy remains constrained by resistance. Ferroptosis, novel programmed cell death modality characterized iron-dependent lipid peroxidation, has emerged as promising frontier in oncology. This review is first summarize mechanisms of action associated both ferroptosis PARP ovarian cancer.

Language: Английский

Research progress on ferroptosis and PARP inhibitors in ovarian cancer: action mechanisms and resistance mechanisms DOI Creative Commons
Jiqing Zhang, Dan Ouyang, Mu Liu

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: April 24, 2025

Ovarian cancer, a gynecologic malignancy with high mortality rates, faces persistent therapeutic challenges due to acquired resistance and frequent recurrence conventional therapies. While poly (ADP-ribose) polymerase (PARP) inhibitors have primarily transformed clinical outcomes through the synthetic lethality mechanism, their long-term efficacy remains constrained by resistance. Ferroptosis, novel programmed cell death modality characterized iron-dependent lipid peroxidation, has emerged as promising frontier in oncology. This review is first summarize mechanisms of action associated both ferroptosis PARP ovarian cancer.

Language: Английский

Citations

0